Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian F Gage

Showing results (11-20 of 139) with videos related to

Pageof 14
Sort By:
Journal of General Internal Medicine|May 8, 2015
Clinical Benefit of American College of Chest Physicians Versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial FibrillationAmbar A Andrade, Brian F Gage
Journal of Thrombosis and Thrombolysis|February 5, 2004
Pharmacogenetics and anticoagulant therapyBrian F Gage, Charles S Eby
Circulation|May 25, 2011
Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillationShimoli V Shah, Brian F Gage
JAMA|February 11, 2005
Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillationCara L O'Brien, Brian F Gage
Clinics in Chest Medicine|April 11, 2003
Outpatient treatment of acute venous thromboembolic diseaseRoger D Yusen, Brian F Gage
Journal of Thrombosis and Thrombolysis|October 2, 2007
Pharmacogenetics of warfarin: regulatory, scientific, and clinical issuesBrian F Gage, Lawrence J Lesko
Journal of the American College of Cardiology|January 26, 2013
The analysis of bleeding risk-prediction scores should include all major bleedsBrian F Gage, Martha J Radford
Personalized Medicine|May 23, 2018
Couma-Gen: implications for future randomized trials of pharmacogenetic-based warfarin therapyLawrence J Lesko, Brian F Gage
Thrombosis Research|July 27, 2005
Pharmacology and pharmacogenetics of warfarin and other coumarins when used with supplementsBrian F Gage, Paul E Milligan
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 29, 2005
Use of EPO in critically ill patients with acute renal failure requiring renal replacement therapyJeanie Park, Brian F Gage, Anitha Vijayan
Pageof 14

Showing results (11-20 of 139) with videos related to

Sort By:
Pageof 14
Journal of General Internal Medicine|May 8, 2015
Clinical Benefit of American College of Chest Physicians Versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial FibrillationAmbar A Andrade, Brian F Gage
Journal of Thrombosis and Thrombolysis|February 5, 2004
Pharmacogenetics and anticoagulant therapyBrian F Gage, Charles S Eby
Circulation|May 25, 2011
Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillationShimoli V Shah, Brian F Gage
JAMA|February 11, 2005
Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillationCara L O'Brien, Brian F Gage
Clinics in Chest Medicine|April 11, 2003
Outpatient treatment of acute venous thromboembolic diseaseRoger D Yusen, Brian F Gage
Journal of Thrombosis and Thrombolysis|October 2, 2007
Pharmacogenetics of warfarin: regulatory, scientific, and clinical issuesBrian F Gage, Lawrence J Lesko
Journal of the American College of Cardiology|January 26, 2013
The analysis of bleeding risk-prediction scores should include all major bleedsBrian F Gage, Martha J Radford
Personalized Medicine|May 23, 2018
Couma-Gen: implications for future randomized trials of pharmacogenetic-based warfarin therapyLawrence J Lesko, Brian F Gage
Thrombosis Research|July 27, 2005
Pharmacology and pharmacogenetics of warfarin and other coumarins when used with supplementsBrian F Gage, Paul E Milligan
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 29, 2005
Use of EPO in critically ill patients with acute renal failure requiring renal replacement therapyJeanie Park, Brian F Gage, Anitha Vijayan
Pageof 14